Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The present study aimed to investigate the value of apolipoproteins, including ApoA-1, ApoC-III, and ApoE, in patients with small cell lung cancer (SCLC) as potential biomarkers for diagnosis, prognosis, and cancer progression. Materials and Methods: Lung samples were collected from 89 patients with SCLC. Nineteen lung samples from non-small cell lung cancer (NSCLC) patients and 12 normal lung tissues were used as controls. Expression profiles of ApoA-1, ApoC-III, and ApoE in different samples were examined using immunohistochemical methods, and the expression levels were correlated with cancer types, treatment, and outcomes using chi-square and Mann-Whitney tests. Results: Expression of ApoA-1 and ApoC-III in SCLC was significantly different, compared with that in NSCLC and normal lung tissues, and was correlated with recurrence of SCLC. Patients undergoing neoadjuvant chemotherapy before surgery showed significantlyreduced expression of ApoA-1 and increased expression of ApoC-III and ApoE. Nevertheless, the expression levels of ApoA-1, ApoC-III, and ApoE were not correlated with SCLC staging. Conclusion: ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC. ApoA-1, ApoC-III, and ApoE may be used to monitor the efficacy of chemotherapy.
Abstract
Purpose: The present study aimed to investigate the value of apolipoproteins, including ApoA-1, ApoC-III, and ApoE, in patients with small cell lung cancer (SCLC) as potential biomarkers for diagnosis, prognosis, and cancer progression. Materials and Methods: Lung samples were collected from 89 patients with SCLC. Nineteen lung samples from non-small cell lung cancer (NSCLC) patients and 12 normal lung tissues were used as controls. Expression profiles of ApoA-1, ApoC-III, and ApoE in different samples were examined using immunohistochemical methods, and the expression levels were correlated with cancer types, treatment, and outcomes using chi-square and Mann-Whitney tests. Results: Expression of ApoA-1 and ApoC-III in SCLC was significantly different, compared with that in NSCLC and normal lung tissues, and was correlated with recurrence of SCLC. Patients undergoing neoadjuvant chemotherapy before surgery showed significantlyreduced expression of ApoA-1 and increased expression of ApoC-III and ApoE. Nevertheless, the expression levels of ApoA-1, ApoC-III, and ApoE were not correlated with SCLC staging. Conclusion: ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC. ApoA-1, ApoC-III, and ApoE may be used to monitor the efficacy of chemotherapy.
참고문헌 (44)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
- Jackman DM, "Small-cell lung cancer", Lancet, 366, pp.1385~1396 (2005)
- Harmsma M, "Serum markers in small cell lung cancer: opportunities for improvement", Biochim Biophys Acta, 1836, pp.255~272 (2013)
- Pillai RN, "Small cell lung cancer: therapies and targets", Semin Oncol, 41, pp.133~142 (2014)
- van Meerbeeck JP, "Small-cell lung cancer", Lancet, 378, pp.1741~1755 (2011)
- Talmud PJ, "The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes", Curr Opin Lipidol, 274(81) (2014)
- Schilling S, "APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis", Neurology, 81, pp.292~300 (2013)
- Podzielinski I, "Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer", Cancer Invest, 31, pp.258~272 (2013)
- Honda K, "Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation", PLoS One, 7, pp.e46908~ (2012)
- Shi J, "Identification of candidate serum biomarkers for small cell lung cancer by proteomics analysis", Minerva Med, 105, pp.137~147 (2014)
- Bradley JD, "Positron emission tomography in limited-stage smallcell lung cancer: a prospective study", J Clin Oncol, 22, pp.3248~3254 (2004)
- Shepherd FA, "The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer", J Thorac Oncol, 2, pp.1067~1077 (2007)
- Ploenes T, "Surgical treatment of early stage small cell lung cancer", Asian Cardiovasc Thorac Ann, 20, pp.694~698 (2012)
- Lee CB, "Current and evolving treatment options for limited stage small cell lung cancer", Curr Opin Oncol, 18, pp.162~172 (2006)
- Cooper WA, "Molecular biology of lung cancer", J Thorac Dis, 5(Suppl 5), pp.S479~S490 (2013)
- Zhang Y, "The development of targeted therapy in small cell lung cancer", J Thorac Dis, 5, pp.538~548 (2013)
- Lund EL, "Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro", Clin Cancer Res, 6, pp.4287~4291 (2000)
- Chetty PS, "Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry", Proc Natl Acad Sci U S A, 106, pp.19005~19010 (2009)
- Tuft Stavnes H, "APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival", Am J Clin Pathol, 142, pp.51~57 (2014)
- Ehmann M, "Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling", Pancreas, 34, pp.205~214 (2007)
- Yang HH, "Lipoprotein (a) level and its association with tumor stage in male patients with primary lung cancer", Clin Chem Lab Med, 47, pp.452~457 (2009)
- Li C, "Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis", Biochem Biophys Res Commun, 446, pp.1047~1052 (2014)
- Gourin CG, "Proteomic identification of serum biomarkers for head and neck cancer surveillance", Laryngoscope, 119, pp.1291~1302 (2009)
- Gao F, "L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF", basic FGF signaling pathways, 2011, pp.3, 479~489
- Larsson M, "Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets", J Biol Chem, 288, pp.33997~34008 (2013)
- Yao Z, "Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production", Curr Opin Lipidol, 23, pp.206~212 (2012)
- Fan Y, "Discovery and identification of potential biomarkers of papillary thyroid carcinoma", Mol Cancer, 8, pp.79~ (2009)
- Kardassis D, "SMAD proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4", Biol Chem, 275, pp.41405~41414 (2000)
- Fraser JD, "DNA binding and transcription activation specificity of hepatocyte nuclear factor 4", Nucleic Acids Res, 26, pp.2702~2707 (1998)
- Reilly M, "Apolipoprotein E and coronary disease: a puzzling paradox", PLoS Med, 3, pp.e258~ (2006)
- Martínez-Clemente M, "5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice", Hepatology, 51, pp.817~827 (2010)
- Su WP, "Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer", Lung Cancer, 71, pp.28~33 (2011)
- Trost Z, "Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients", Arch Med Res, 39, pp.663~667 (2008)
- Zelen M, "Keynote address on biostatistics and data retrieval", Cancer Chemother Rep 3, 4, pp.31~42 (1973)
- Cheng T, "Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinumbased chemotherapy in advanced non-small cell lung cancer", Med Oncol, 32, pp.407~ (2015)
- Ko HL, "APOC1 as a novel diagnostic and prognostic biomarker for lung cancer: a marker phase i trial", Thoracic Cancer, 5, pp.500~508 (2014)
- Fox W, "Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up", Lancet, 2, pp.63~65 (1973)
- Shepherd FA, "Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer", J Thorac Cardiovasc Surg, 86, pp.498~506 (1983)
- Koletsis EN, "Current role of surgery in small cell lung carcinoma", J Cardiothorac Surg, 4, pp.30~ (2009)
- Turrisi AT 3rd, "Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide", N Engl J Med, 340, pp.265~271 (1999)
- Naranjo Gómez JM, "Behaviour and survival of high-grade neuroendocrine carcinomas of the lung", Respir Med, 104, pp.1929~1936 (2010)
- Yip D, "Predictive and prognostic factors in small cell lung cancer: current status", Lung Cancer, 28, pp.173~185 (2000)
- Foster NR, "Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials", Cancer, 115, pp.2721~2731 (2009)